• 생명과학회지
• /
• 제31권4호
• /
• pp.400-409
• /
• 2021

천연 benzophenanthridine alkaloid의 일종인 sanguinarine에 의한 인간 암세포에서의 세포사멸 유도는 암 치료를 위한 잠재적 치료 가능성으로 여겨져 왔으나 기본적인 항암 기전은 여전히 불분명하다. 종양 억제제 p53의 결실 또는 돌연변이는 결장암세포의 항암제 내성에 대한 주요 원인으로 작용하다. 따라서, 본 연구에서는 정상 p53을 가진 HCT116 (p53+/+) 및 p53이 결여된 HCT116 (p53-/-) 결장암세포를 대상으로 sanguinarine에 의해 유도되는 세포사멸에서 p53의 역할을 조사하였다. 본 연구의 결과에 의하면, sanguinarine은 HCT116 (p53-/-) 세포에 비하여 HCT116 (p53+/+) 세포의 생존력을 현저히 감소시켰다. 아울러 sanguinarine은 HCT116 (p53-/-) 세포보다 HCT116 (p53+/+) 세포에서 p53 및 cyclin-dependent kinase 억제제 p21^WAF1/CIP1의 발현을 증가시키면서 DNA 손상 및 세포사멸의 유도를 증가시켰다. Sanguinarine은 HCT116 (p53+/+) 세포에서 외인성 및 내인성 세포사멸의 개시에 관여하는 caspase-8 및 caspase-9의 활성을 증가시켰으며, 전형적인 효과기 caspase인 caspase-3을 활성화시켰다. 또한, sanguinarine은 HCT116 (p53+/+) 세포에서 Bax/Bcl-2의 발현 비율을 증가시키고 미토콘드리아 손상을 유발하였지만, HCT116 (p53-/-) 세포에서는 이러한 현상이 관찰되지 않았다. 결론적으로 본 연구의 결과는 sanguinarine은 HCT116 결장암세포에서 p53 의존적으로 외인성 및 내인성 세포사멸의 경로 활성을 통하여 세포사멸을 유도하였음을 의미한다.

• Journal of Trauma and Injury
• /
• 제22권2호
• /
• pp.134-141
• /
• 2009

Purpose: Patients with traumatic brain injury (TBI) were referred from other hospitals for further management. In addition, patients routinely underwent computed tomography examinations of the head (HCT) in the referral hospitals. The purpose of this study was to evaluate retrospectively the utility of routine HCT scans according to the severity of TBI. Methods: Patients with TBI referred to our hospital between December 2005 and July 2008 were included in this study. We investigated HCT findings, indications for repeat HCT examinations (routine versus a neurological change), and neurosurgical interventions. The head injury severity was divided into three categories according to the Glasgow Coma Scale (GCS) score, including mild, moderate, and severe TBI. The use of neurosurgical interventions between patients who underwent routine HCT scans and patients who underwent HCT scans for a neurological change were compared according to the severity of TBI. Results: A total of 81 patients met the entry criteria for this study. Among these patients, 67%(n=54) of the patients underwent HCT scans on a routine basis, whereas 33%(n=27) of the patients underwent HCT scans for a neurological change. A total of 21 patients showed signs of a worsening condition on the HCT scans. Neurosurgical intervention was required for 23(28.4%) patients. For patients who underwent routine HCT examinations, no patient with mild TBI underwent a neurosurgical intervention. However, one patient with moderate TBI and three(13%) patients with severe TBI underwent neurosurgical interventions. The kappa index, the level of agreement for HCT indications of intervention and referral reasons for intervention, was 0.65 for high hierarchy hospitals and 0.06 for low hierarchy hospitals. Conclusion: Routine serial HCT examinations in the referred hospitals would be useful for patients with severe head injury and for patients from low hierarchy hospitals where no emergency physicians or neurosurgeons are available.

• Journal of Nutrition and Health
• /
• 제24권5호
• /
• pp.450-457
• /
• 1991

본 연구는 생화학적 검사에 의한 철 영양상태의 판정시 검사항목에 따른 판정의 정확도를 보기 위하여 외견상 건강한 18~21세의 여대생 57명을 대상으로 혈액성분 중 Hb, Hct, serum ferritin을 측정하고 그 상관성을 분석하였다. 1) 조사대상자의 Hb는 평균이 $13.9\pm0.96g/dl,$ 중앙값이 14.1g/dl 였다. Hct의 평균은 $41.4\pm2.85%,$ 중앙값은 42.0%였고, ferritin은 평균 $20.7\pm15.5ng/ml,$ 중앙값 16.5ng/ml, 최빈값 3.40ng/ml 였다. Hb, Hct, ferritin값 모두 Kolmogorov-Smirnov test결과 정규분포 하는 것으로 나타났다. 2) Hb와 Hct간에는 r=0.9467(p<0.001)로 (Hct=2.28+2.81$\times$Hb)의 회귀관계를 보였다. Hb와 ferritin간에는 r=0.5396(p<0.001)로 $\times$Hb)를, Hct와 ferritin간에는 r=0.5591(p<0.001)로 (log(ferritin)=-1.73+0.07$\times$Hct>의 회귀식이 구해졌다. 3) 빈혈발현율은 Hb 12g/dl를 기준시 5.3%, Hct 36% 기준시 10.5%, ferritin 12ng/ml 기준시 36.8% 였다. 4) Ferritin 함량을 기준하여 Hb, Hct판정에 대한 신뢰도를 분석한 결과, 빈혈 판정시 많이 이용되는 Hb 12g/dl 미만이나 Hct 36% 이하를 기준했을 때 두 방법 모두 sensitivity가 매우 낮았으며 specificity는 매우 높은 값을 보여, 빈혈 발현율이 높은 우리나라의 경우 Hb나 Hct의 판정기준치를 높일 필요가 있는 것으로 나타났다. 5) 빈혈 판정을 위한 검사방법으로서의 Hb측정은 sensitivity, specificity 등을 고려할 때 판정 기준치를 14g/dl로 하는 것이 타당할 것으로 보인다. Hct의 경우 판정치를 40%로 높일 경우에 false-negative rate가 42.9%로 낮아졌다.

• 생명과학회지
• /
• 제23권10호
• /
• pp.1230-1238
• /
• 2013

$17{\alpha}$-estradiol ($17{\alpha}-E_2$)의 에폽토시스 유도활성에 미치는 종양억제단백질 p53의 조절효과를 조사하고자, $17{\alpha}-E_2$에 의해 유도되는 에폽토시스 현상들을 인체 대장암 세포주 유래 클론인 HCT116 ($p53^{+/+}$) 및 HCT116 ($p53^{-/-}$) 세포에서 비교하였다. HCT116 ($p53^{+/+}$) 및 HCT116 ($p53^{-/-}$) 세포를 $17{\alpha}-E_2$ ($2.5{\sim}10{\mu}M$)로 처리하거나 혹은 HCT116 ($p53^{+/+}$) 및 HCT116 ($p53^{-/-}$) 세포를 $10{\mu}M$ $17{\alpha}-E_2$로 시간 별로 처리한 결과, HCT116 ($p53^{+/+}$)에 있어서는 세포독성과 에폽토시스-관련 sub-G1 peak의 비율은 처리농도와 시간에 의존적으로 나타났다. 그러나 HCT116 ($p53^{-/-}$) 세포의 경우는 이러한 현상이 미약하게 나타났다. $17{\alpha}-E_2$에 의해 유도되는 비정상적 유사분열방추사 형성, 중기판 염색체 배열의 미완성, 이에 따른 유사분열정지($G_2/M$ arrest) 등의 현상은 HCT116 ($p53^{+/+}$) 및 HCT116 ($p53^{-/-}$) 세포에서 유사한 수준으로 나타났다. 이에 반해, $17{\alpha}-E_2$에 의해 유도되는 Bak과 Bax의 활성화, 미토콘드리아의 막전위 상실(${\Delta}{\Psi}m$ loss), 그리고 PARP 분해 등의 현상은 HCT116 ($p53^{-/-}$) 세포에 비해 HCT116 ($p53^{+/+}$) 세포에서 훨씬 높은 수준으로 확인되었다. 아울러 $17{\alpha}-E_2$로 처리된 HCT116 ($p53^{+/+}$) 세포에서 확인되는 p53 (Ser-15)의 인산화 및 p53 수준의 증가와 일치하여, 세포 내의 p21및 Bax 수준도 현저히 증가하였다. 이때 $17{\alpha}-E_2$로 처리된 HCT116 ($p53^{-/-}$) 세포에서는 p21 및 Bax의 발현수준이 매우 낮았다. 한편, 에폽토시스 억제단백질인 Bcl-2 단백질 수준은 HCT116 ($p53^{-/-}$) 세포에 비해 HCT116 ($p53^{+/+}$) 세포에서 다소 낮았으나, 이러한 Bcl-2 단백질 수준은 $17{\alpha}-E_2$ 처리 후에도 크게 변화하지 않는 것으로 나타났다. 이러한 결과들은 $17{\alpha}-E_2$ 처리에 의해 유도되는 에폽토시스 유도 경로의 구성원들의 변화, 즉 비정상적 유사분열방추사 형성 및 이에 따른 유사분열정지($G_2/M$ arrest), 뒤이은 Bak 및 Bax의 활성화, 미토콘드리아의 막전위 상실, 그리고 이에 수반되는 caspase cascade 활성화 및 PARP 분해로 진행되는 에폽토시스 현상들 중에서, Bak 및 Bax의 활성화 단계가 종양억제단백질 p53의 에폽토시스 증진 활성에 의해 양성적으로 조절되는 작용 타켓임을 보여준다.

• 대한의생명과학회지
• /
• 제20권1호
• /
• pp.32-38
• /
• 2014

Potassium cyanate (KOCN) that is known as an inducer of the protein carbamylation is an inorganic compound and is the conjugate based of cyanic acid (HOCN). Based on these studies, we confirmed that KOCN induces the apoptosis of the human colorectal cancer cell line, HCT 116 cells, by various mitochondrial pathways. To investigate other mechanisms of KOCN-mediated apoptosis, in the present study, we examined KOCN-induced cytokines production in HCT 116 cells and identified the intracellular signaling pathway in these processes. We first demonstrated that KOCN considerably increased the cell apoptosis via intracellular $Ca^{2+}$ signaling, mitochondrial dysfunction and ROS production. And then we examined TNF-${\alpha}$ and IL-$1{\beta}$ levels mediated by KOCN in HCT 116 cells. Although IL-$1{\beta}$ was not involved in KOCN-mediated HCT 116 cell apoptosis, the release of TNF-${\alpha}$ was mediated by KOCN in HCT 116 cells via NF-${\kappa}B$ activation. Apoptosis was also enhanced by incubation with supernatants from HCT 116 cells after KOCN treatment and this effect was partially reduced by BAY 11-7085 pre-treated supernatant. Taken together, our results indicate that KOCN-induced apoptosis in HCT 116 cells is dependent on the releases of TNF-${\alpha}$ and the increased factors and that the mechanism involves the activation of NF-${\kappa}B$.

• 대한의생명과학회지
• /
• 제29권4호
• /
• pp.287-295
• /
• 2023

Amifostine was developed to protect cells, but it is known to induce cytotoxicity and apoptosis, and the exact mechanism is unknown. In this study, we investigated how the DNA mismatch repair (MMR) system interacts with p53 to prevent apoptosis, cell cycle arrest, and cytoprotective effects induced by amifostine. HCT116 colon cancer cells sublines HCT116/p53+,HCT116/p53+, HCT116/p53-, HCT116/E6 and HCT116+ch3/E6 cells were used for evaluation. Amifostine induced G1 arrest and increased toxicity two-fold in p53- cells regardless of MMR expression. Both G1 cell cycle arrest and induction of p53 protein peaked at 24 h after the start of amifostine exposure. Both G1 cell cycle arrest and induction of p53 protein peaked at 24 h after the start of amifostine exposure. Amifostine induced the expression of p21 protein in both p53+ and p53- cells. As for apoptosis, compared to p53- cells, p53+ cells showed 3.5~4.2 times resistance to amifostine-induced apoptosis. HCT116+E6 with both p53 and MMR loss showed maximum apoptosis at 48 h, and HCT116+ch3/E6HCT116+ch3/E6 with p53 loss showed maximum apoptosis at 24 h. As a result, it was confirmed through in vitro experiments that amifostine-induced G1 cell cycle arrest and apoptosis are mediated through a pathway dependent on MMR and p53 protein.

• 대한한의학회지
• /
• 제23권2호
• /
• pp.19-27
• /
• 2002

Objective : This study was designed to investigate the effect of Hyeolbuchukeo-tang (HCT) on NO production and the molecular mechanism of NO production modulated by HCT in the primary VSMC (vascular smooth muscle cells). Method : Primary VSMC was established from aorta and cultured VSMC used in this study. NO production of VSMC was assayed by Griess reagent and the expression of iNOS gene was assayed by Western, RT-PCR. Result : $TNF-{\gamma}$ induced NO production, but $IFN-{\gamma}$ or HCT alone did not induce NO production in cultured VSMC. However, $IFN-{\gamma}$ or HCT potentiated NO production in $TNF-{\gamma}-treated$ VSMC in a time- and dose-dependent manner. $TNF-{\gamma}$ induced the iNOS gene expression corresponding to NO production in $TNF-{\gamma}-treated$ VSMC. HCT potentiated NO production in $TNF-{\gamma}-treated$ VSMC by about 20%, but HCT did not increase the level of iNOS mRNA in $TNF-{\gamma}-treated$ VSMC. HCT slightly increased the level of iNOS protein in $TNF-{\gamma}-treated$ VSMC. Calcium ionophore A23187 decreased NO production in $TNF-{\gamma}-treated$ VSMC, but HCT attenuated the effect of A23187. Conclusion : As NO is deeply involved in the development of arteriosclerosis and dilation of blood vessels, drugs or chemicals modulating NO production in VSMC could be used for preventing and treating arteriosclerosis. Considering the effect of HCT on the modulation of NO production in VSMC, MCT has a potential capacity for preventing and treating diseases of the circulation system including arteriosclerosis.

• BLOOD RESEARCH
• /
• 제53권4호
• /
• pp.288-293
• /
• 2018

Background Although allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for myelodysplastic syndrome (MDS), a substantial number of patients experience relapse. We reviewed the clinical outcomes of patients with MDS who relapsed after allogeneic HCT. Methods Thirty patients who experienced relapse or progression after allogeneic HCT for MDS between July 2000 and May 2016 were included in this retrospective analysis. Results The median time from HCT to relapse was 6.6 (range, 0.9-136.3) months. Donor lymphocyte infusions (DLIs) were administered to four patients: one achieved complete remission (CR) and survived disease free, while three did not respond to DLI and died. Hypomethylating agents were administered to seven patients: one who had stable disease continuously received decitabine, while six died without response to treatment. Six patients received AML-like intensive chemotherapy, and three achieved CR: two underwent second HCT and one DLI. One patient receiving second HCT survived without disease, but the other two relapsed and died. Three, four, and eight patients who did not respond to intensive chemotherapy, low-dose cytarabine, and best supportive care, respectively, died. One patient who underwent second HCT following cytogenetic relapse survived disease free. Median overall survival after relapse was 4.4 months, and relapse within 6 months after HCT was associated with shorter survival. Conclusion Outcomes of MDS patients relapsing after allogeneic HCT were disappointing. Some patients could be saved using DLI or second HCT.

• The Korean Journal of Physiology and Pharmacology
• /
• 제26권3호
• /
• pp.195-205
• /
• 2022

Determining blood loss [100% - RBV (%)] is challenging in the management of haemorrhagic shock. We derived an equation estimating RBV (%) via serial haematocrits (Hct₁, Hct₂) by fixing infused crystalloid fluid volume (N) as [0.015 × body weight (g)]. Then, we validated it in vivo. Mathematically, the following estimation equation was derived: RBV (%) = 24k / [(Hct₁ / Hct₂) -1]. For validation, non-ongoing haemorrhagic shock was induced in Sprague-Dawley rats by withdrawing 20.0%-60.0% of their total blood volume (TBV) in 5.0% intervals (n = 9). Hct₁ was checked after 10 min and normal saline N cc was infused over 10 min. Hct₂ was checked five minutes later. We applied a linear equation to explain RBV (%) with 1 / [(Hct₁ / Hct₂) -1]. Seven rats losing 30.0%-60.0% of their TBV suffered shock persistently. For them, RBV (%) was updated as 5.67 / [(Hct₁ / Hct₂) -1] + 32.8 (95% confidence interval [CI] of the slope: 3.14-8.21, p = 0.002, R² = 0.87). On a Bland-Altman plot, the difference between the estimated and actual RBV was 0.00 ± 4.03%; the 95% CIs of the limits of agreements were included within the pre-determined criterion of validation (< 20%). For rats suffering from persistent, non-ongoing haemorrhagic shock, we derived and validated a simple equation estimating RBV (%). This enables the calculation of blood loss via information on serial haematocrits under a fixed N. Clinical validation is required before utilisation for emergency care of haemorrhagic shock.

• Journal of mucopolysaccharidosis and rare diseases
• /
• 제5권1호
• /
• pp.12-16
• /
• 2021

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans (GAGs), which affects multiple organs and systems. Current treatments for MPS II include enzyme replacement therapy (ERT) and hematopoietic cell transplantation (HCT) to reduce the accumulation of GAGs. HCT has the potential advantage that donor-derived enzyme-competent cells can provide a continuous secreting source of the enzyme. However, HCT as a treatment for MPS II remains controversial because its effectiveness is unclear, particularly in terms of neurological symptoms. To date, several clinical experiences with HCT in MPS II have been reported. In this paper, we review post-HCT outcomes in the previously published literature and discuss the effects of HCT on each of the clinical signs and symptoms of MPS II.